Skip to content

EyePoint, Inc. EYPT Debt-to-equity

Debt-to-equity at other companies

Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
0.1×-0.2×
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
0.5×-0.1×
HRO
HarrowHROW
10.7×+2.6×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
3.7×

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

Based on the most recent quarter.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's debt-to-equity?
EyePoint, Inc. (EYPT) reported debt-to-equity of 0.1× in Q1 2026.
How has EyePoint, Inc. 's debt-to-equity changed year-over-year?
EyePoint, Inc. 's debt-to-equity increased by 20.0% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for EyePoint, Inc. 's debt-to-equity?
Over 5 years (2020 to 2025), EyePoint, Inc. 's debt-to-equity has grown at a -49.3% compound annual growth rate (CAGR), from 2.2× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.